Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | JAK2 | O60674 | 2/20 | 0.37 |
| ▸ | JAK1 | P23458 | 2/20 | 0.37 |
| ▸ | KEAP1 | Q14145 | 3/20 | 0.33 |
| ▸ | NFE2L2 | Q16236 | 1/20 | 0.33 |
| ▸ | GLO1 | Q04760 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.33 |
| ▸ | PGR | P06401 | 1/20 | 0.33 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.33 |
| ▸ | AR | P10275 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TYK2 | P29597 | 1/20 | 0.31 |
| ▸ | JAK3 | P52333 | 1/20 | 0.31 |
| ▸ | EP300 | Q09472 | 1/20 | 0.31 |
| ▸ | KAT2B | Q92831 | 1/20 | 0.31 |
| ▸ | KAT8 | Q9H7Z6 | 1/20 | 0.31 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | HPGD | P15428 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5360360 | 0.83 | PSIP1 (0.38) | JAK2JAK1HTTL3MBTL1TYK2 | |
| SCHEMBL5360047 | 0.73 | KAT2B (0.33) | KAT2BKDM4E | |
| SCHEMBL5349580 | 0.73 | AR (0.36) | AR | |
| SCHEMBL5359923 | 0.71 | ALDH1A1 (0.35) | KDM4EMAPTHPGDHSD17B10 | |
| SCHEMBL5366873 | 0.67 | MAPT (0.34) | JAK2JAK1KEAP1NFE2L2GLO1 | |
| SCHEMBL5353125 | 0.63 | — | — | |
| SCHEMBL5358925 | 0.62 | — | — | |
| SCHEMBL9450334 | 0.62 | KEAP1 (0.42) | JAK2JAK1KEAP1NFE2L2GLO1 | |
| SCHEMBL5354802 | 0.62 | PDPK1 (0.32) | AR | |
| SCHEMBL2066412 | 0.58 | KEAP1 (0.38) | JAK2JAK1KEAP1NFE2L2GLO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | claimed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | claimed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | claimed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | claimed |
| EP-1553096-B1 | PYRAZOLE COMPOUNDS | UBE INDUSTRIES (JP) | 2012-10-31 | — | — | EP | disclosed |
| US-7294625-B2 | Pyrazole compounds | UBE INDUSTRIES, LTD. (JP) | 2007-11-13 | — | — | US | disclosed |
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | UBE INDUSTRIES, LTD. (JP) | 2006-03-23 | — | — | US | disclosed |
| EP-1553096-A1 | PYRAZOLE COMPOUNDS | Ube Industries, Ltd. (JP) | 2005-07-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060063934-A1 | 3-Pyridazonyl- or triazolopyridazinyl- 4-pyridinyl- or pyrimidinyl- pyrazoles, e.g., 4-(2-aminopyridin-4-yl)-3-phenyl-1-([1,2,4]triazolo[4,3-b]pyridazin-6-yl)-1H-pyrazole; p38MAP kinase inhibitors, used to treat rheumatoid arthritis | CNKSR1, MAPK1, MAPK3 | JAK2 31/4885JAK1 34/4885KEAP1 1730/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.